Article Sidebar

PDF (Tiếng Việt)
Published: 2024-09-11
Abstract Views: 295
Views PDF (Tiếng Việt): 211
DOI: https://doi.org/10.52852/tcncyh.v180i7.2539
Issue
Vol. 180 No. 7 (2024)
Section
Các bài báo
How to Cite
Hùng, K. Đình ., Dung, Đặng T. N. ., Hệ, Đồng V. ., Trang, L. V. H. ., Hoa, N. D. ., Dinh, N. T. ., & Trang, P. T. H. . (2024). 1. Evaluating the impact of IDH1 gene mutation and MGMT gene methylation on overall survival time in patients with glioblastoma. Journal of Medical Research, 180(7), 1-9. https://doi.org/10.52852/tcncyh.v180i7.2539

1. Evaluating the impact of IDH1 gene mutation and MGMT gene methylation on overall survival time in patients with glioblastoma

Kieu Dinh Hung, Dang Thi Ngoc Dung, Dong Van He, Le Vu Huyen Trang, Ngo Dieu Hoa, Nguyen Thi Dinh, Pham Thi Huong Trang

Main Article Content

Abstract

Mutation of the IDH1 gene (IDH1-m) and methylation of the MGMT gene (Methyl-MGMT) are molecular genetic markers that play a crucial role in the prognosis of patients with glioblastoma. A cross-sectional, retrospective study was conducted on 129 patients with glioblastoma who underwent tumor resection at Viet Duc University Hospital and Hanoi Medical University Hospital from 2017 to 2021. The results of the study showed that age < 65 (p = 0.003), IDH1-m (p = 0.036), and Methyl-MGMT (p = 0.043) are independent prognostic factors for overall survival (OS). OS in the Methyl-MGMT & IDH1-m group (median 20.5 months) was significantly higher compared to the Methyl-MGMT or IDH1-m group (median 9.6 months) and the UnMethyl-MGMT & IDH1-wt group (median 5.8 months) with p = 0.007.

Article Details

Keywords

IDH1 gene mutation, MGMT gene methylation, Glioblastoma, overall survival

References

1. Hanif F, Muzaffar K, Perveen K, et al. Glioblastoma Multiforme: A Review of its Epidemiology and Pathogenesis through Clinical Presentation and Treatment. Asian Pac J Cancer Prev APJCP. 2017;18(1):3-9. doi:10.22034/APJCP.2017.18.1.3
2. Lönn S, Klaeboe L, Hall P, et al. Incidence trends of adult primary intracerebral tumors in four Nordic countries. Int J Cancer. 2004;108(3):450-455. doi:10.1002/ijc.11578
3. Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012;483(7390):479-483. doi:10.1038/nature 10866
4. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 Mutations in Gliomas. N Engl J Med. 2009;360(8):765-773. doi:10.1056/NEJM oa0808710
5. Tran AN, Lai A, Li S, et al. Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry. Neuro-Oncol. 2014;16(3):414-420. doi:10.1093/neuonc/not 198
6. Wahl DR, Dresser J, Wilder-Romans K, et al. Glioblastoma Therapy Can Be Augmented by Targeting IDH1-Mediated NADPH Biosynthesis. Cancer Res. 2017;77(4):960-970. doi:10.1158/0008-5472.CAN-16-2008
7. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol (Berl). 2016;131(6):803-820. doi:10.1007/s00401-01 6-1545-1
8. Wick W, Meisner C, Hentschel B, et al. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology. 2013;81(17):1515-1522. doi:10.1212/WNL.0b013e3182a95680
9. Carrillo JA, Lai A, Nghiemphu PL, et al. Relationship between Tumor Enhancement, Edema, IDH1 Mutational Status, MGMT Promoter Methylation, and Survival in Glioblastoma. Am J Neuroradiol. 2012;33(7):1349-1355. doi:10.3174/ajnr.A2950
10. Molenaar RJ, Verbaan D, Lamba S, et al. The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. Neuro-Oncol. 2014;16(9):1263-1273. doi:10.1093/neuonc/nou005
11. Andreas von D, Andrey K, Christian H. The Next Generation of Glioma Biomarkers: MGMT Methylation, BRAF Fusions and IDH1 Mutations. Brain Pathology. Accessed October 6, 2021. https://onlinelibrary.wiley.com/doi/10.1111/j.1750-3639.2010.00454.x
12. Hegi ME, Stupp R. Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter-still a dilemma? Neuro-Oncol. 2015;17(11):1425-1427. doi:10.1 093/neuonc/nov198
13. Trần Kim Tuyến. Nghiên cứu đột biến gen IDH1/2 của u nguyên bào thần kinh đệm lan tỏa ở người trưởng thành. Luận án Tiến sĩ Y học. Đại học Y Dược Thành phố Hồ Chí Minh; 2022.
14. Trần Anh Đức. Nghiên cứu đột biến gen IDH, P53, methyl hóa promoter gen MGMT và kết quả điều trị u tế bào thần kinh đệm bậc cao. Luận án Tiến sĩ y học. Học viện Quân y; 2023.
15. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO Classification of Tumours of the Central Nervous System. Acta Neuropathol (Berl). 2007;114(2):97-109. doi:10.1007/s00 401-007-0243-4
16. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807-1812. doi:10.1126/scien ce.1164382
17. Jovanović N, Mitrović T, Cvetković VJ, et al. Prognostic significance of MGMT promoter methylation in diffuse glioma patients. Biotechnol Biotechnol Equip. 2019;33(1):639-644. doi:10.1080/13102818.2019.1604158
18. Millward CP, Brodbelt AR, Haylock B, et al. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy. Acta Neurochir (Wien). 2016;158(10):1943-1953. doi:10.1007/s00701-016-2928-8